Key facts
- It has raised $175.0M; the latest was Early Stage VC ($175.0M) in Apr 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Tasman Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tasman Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tasman Therapeutics
Operator of a pharmaceutical company intended to focus on developing treatments for neuropsychiatric disorders. The company's product is an extended-release oral ketamine tablet in development for treatment-resistant depression, enabling individuals to address the needs of people living with difficult-to-treat depression.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Ownership
- Privately Held (backing)
Tasman Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tasman Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tasman Therapeutics in its N-PORT filings yet. We sweep new filings monthly.